Hematopoiesis News Volume 6.27 | Jul 14 2015

miR-139-5p Controls Translation in Myeloid Leukemia through EIF4G2
Researchers identified microRNA (miR)-139-5p suppression across several cytogenetically defined acute myeloid leukemia (AML) subgroups. Restoration of mir-139 expression in cell lines representing the major AML subgroups caused cell cycle arrest and apoptosis in vitro and in xenograft mouse models in vivo. [Oncogene] Abstract

The Oncofusion Protein FUS–ERG Targets Key Hematopoietic Regulators and Modulates the All-trans Retinoic Acid Signaling Pathway in t(16;21) Acute Myeloid Leukemia
Researchers showed that FUS–ERG acts in the context of a heptad of proteins central to proper expression of genes involved in maintaining a stem cell hematopoietic phenotype. [Oncogene] Full Article

Inhibition of Thrombopoietin/Mpl Signaling in Adult Hematopoiesis Identifies New Candidates for Hematopoietic Stem Cell Maintenance
The authors constructed an intracellular-truncated, signaling-deficient Mpl protein which is presented on the cell surface. The transplantation of bone marrow cells retrovirally transduced to express dnMpl into wildtype mice induced thrombocytopenia, and a progressive loss of hematopoietic stem cell. [PLoS One] Full Article

Modulation of Hematopoietic Progenitor Cell Fate In Vitro by Varying Collagen Oligomer Matrix Stiffness in the Presence or Absence of Osteoblasts
To recreate the in vivo hematopoietic cell microenvironment or niche and to study the impact of extracellular matrix biophysical properties on hematopoietic progenitor cell (HPC) proliferation and function, mouse bone-marrow derived HPCs were cultured within three-dimensional type I collagen oligomer matrices. [J Immunol Methods] Abstract

A Quantitative Assessment of the Content of Hematopoietic Stem Cells in Mouse and Human Endosteal-Bone Marrow: A Simple and Rapid Method for the Isolation of Mouse Central Bone Marrow
A quantitative and qualitative assessment of cell populations isolated from mouse and human bone marrow was undertaken with a focus on the distribution of hematopoietic cells between the central bone marrow and endosteal bone marrow. [BMC Hematol] Full Article

CLINICAL RESEARCH

Allogeneic Hematopoietic Stem Cell Transplantation for Poor-Risk CLL: Dissecting Immune-Modulating Strategies for Disease Eradication and Treatment of Relapse
To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. [Bone Marrow Transplant] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation in Adults with Myelodysplastic Syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)
In this multicenter retrospective study, investigators analyzed the outcome of adult patients with myelodysplastic syndrome who underwent allogeneic hematopoietic stem cell transplantation in Argentina and evaluated the prognostic factors associated with progression-free survival, overall survival, cumulative incidence of relapse, and non-relapse mortality. [Hematology] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Kite Pharma and The Leukemia & Lymphoma Society^® Enter into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
Kite Pharma, Inc., and The Leukemia & Lymphoma Society announced that they have entered into a partnership to enhance the development of Kite’s lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma. [Kite Pharma, Inc.] Press Release

St. Jude to Receive $12 Million in Grants from NIH
Investigators at St. Jude Children’s Research Hospital have received grants totaling more than $12 million from the National Institutes of Health (NIH)’s Pharmacogenomics Research Network for a new Center for Precision Medicine in Leukemia and for the Clinical Pharmacogenetics Implementation Consortium. [St. Jude Children’s Research Hospital] Press Release

LLS Applauds House Approval of 21^st Century Cures Act
The Leukemia & Lymphoma Society (LLS) commends the U.S. House of Representatives for the overwhelming approval of the 21^st Century Cures Act. This law, if enacted by the full Congress, will significantly speed access to new lifesaving therapies for blood cancer patients. [The Leukemia & Lymphoma Society] Press Release

From our sponsor: Working with blood? Request your free wallchart on human blood cell frequencies.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW PhD Position – Drug Releasing, Nanostructured Biomaterials for Adult Stem Cells (Karlsruhe Institute of Technology)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Splicing in Hematopoiesis (Northwestern University)

Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.